Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF -1.24%60 3-Year EBITDA Growth Rate is 47.30% as of Dec. 2025, which is 85% above its 10-year median of 25.60. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $1.24 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,136 Biotechnology companies, Can Fite Biopharma ranks better than 83.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 47.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 46.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 42.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Can Fite Biopharma was 55.20% per year. The lowest was -13.40% per year. And the median was 25.60% per year.
Can Fite Biopharma (AMEX:CANF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Can Fite Biopharma 3-Year EBITDA Growth Rate Related Terms
CANF vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Can Fite Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's 3-Year EBITDA Growth Rate falls into.
Can Fite Biopharma 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 47.30% mean?
Can Fite Biopharma (CANF) has a 3-Year EBITDA Growth Rate of 47.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Can Fite Biopharma and its competitors. This is 85% above median its historical median of 25.60. According to the industry distribution chart, Can Fite Biopharma ranks #183 out of 1136 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Can Fite Biopharma's 3-Year EBITDA Growth Rate too high?
Can Fite Biopharma's current 3-Year EBITDA Growth Rate of 47.30% is 85% above median its 10-year median of 25.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Can Fite Biopharma's value of 47.30% is 216.4% above this industry median. Based on the distribution chart, Can Fite Biopharma ranks #183 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #183 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Can Fite Biopharma in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.95. Can Fite Biopharma's value of 47.30% is 216.4% above this benchmark. While the company's 10-year median is 25.60 vs. the industry median of 14.95, Can Fite Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current 3-Year EBITDA Growth Rate of 47.30% is 216.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Can Fite Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current 3-Year EBITDA Growth Rate is 47.30%, which is 85% above median its own 10-year median of 25.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $3.19 — trading 157.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 47.30%, which is 85% above median its 10-year median of 25.60 and 216.4% above the Biotechnology industry median of 14.95. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current 3-Year EBITDA Growth Rate is 47.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be overvalued.
The current stock price of $3.19 is trading 157.3% above its estimated GF Value™ of $1.24.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
3-Year EBITDA Growth Rate: 47.30% (85% above median its 10-year median of 25.60)
GF Value™: $1.24 vs. price of $3.19 (157.3% above fair value)
Industry Position: 216.4% above the Biotechnology median (#183 of 1136)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
